INTERIUS BIOTHERAPEUTICS
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.
INTERIUS BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2019-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.interiusbio.com
Total Employee:
11+
Status:
Active
Contact:
610-639-4644
Total Funding:
81.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome Wordpress Plugins Global Site Tag
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arcutis Biotherapeutics
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Current Advisors List
Board_observer
2020-03-01
Board_member
2021-01-01
Board_member
2021-01-01
Current Employees Featured
Saar Gill Founder @ Interius BioTherapeutics
Founder
Philip R. Johnson Chief Executive Officer @ Interius BioTherapeutics
Chief Executive Officer
Bruce A. Peacock Co-Founder @ Interius BioTherapeutics
Co-Founder
Founder
Investors List
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program investment in Series A - Interius BioTherapeutics
Agent Capital
Agent Capital investment in Series A - Interius BioTherapeutics
The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research investment in Series A - Interius BioTherapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Interius BioTherapeutics
Quan Capital
Quan Capital investment in Series A - Interius BioTherapeutics
BrightEdge Fund
BrightEdge Fund investment in Series A - Interius BioTherapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Interius BioTherapeutics
RA Capital Management
RA Capital Management investment in Series A - Interius BioTherapeutics
Logos Capital
Logos Capital investment in Series A - Interius BioTherapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Interius BioTherapeutics
Official Site Inspections
http://www.interiusbio.com
- Host name: interius.tempurl.host
- IP address: 64.176.203.43
- Location: Andover United States
- Latitude: 42.6508
- Longitude: -71.1607
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01810
More informations about "Interius BioTherapeutics"
Meet our leadership team| Interius - Interius Biotherapeutics
Interius BioTherapeutics is a clinical-stage biotechnology company working to expand the potential and reach of genetic medicine by developing next-generation delivery technology.See details»
Interius BioTherapeutics - Crunchbase Company …
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo …See details»
Our platform enables off-the-shelf genetic medicines | Interius
To answer this front-line clinical need, we founded Interius with the intent to “democratize” genetic medicine. We invented a new type of treatment — a platform — which could be used in …See details»
Interius Company Profile 2025: Valuation, Funding
Interius General Information Description. Developer of a gene delivery platform designed to treat hematologic malignancies and other cancers. The …See details»
Interius BioTherapeutics CEO and Key Executive Team - Craft
Interius BioTherapeutics's Vice President, Operations is Dora Mitchell. Other executives include Bruce Peacock, Founder; Saar Gill, Founder, SAB Chair and 2 others. See the full leadership …See details»
Interius BioTherapeutics, Inc. - Drug pipelines, Patents, Clinical ...
For more information, visit www.interiusbio.com and follow us on LinkedIn . SOURCE: Interius BioTherapeutics. Phase 1 Gene Therapy Cell Therapy Immunotherapy IND. 100 Deals …See details»
Interius BioTherapeutics Information - RocketReach
Interius is a clinical stage biotechnology company, engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases.See details»
Interius BioTherapeutics - Overview, News & Similar ... - ZoomInfo
Interius BioTherapeutics contact info: Phone number: (215) 608-9333 Website: www.interiusbio.com What does Interius BioTherapeutics do? Founded in 2021, Interius …See details»
Interius BioTherapeutics - Craft
Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery. It transforms cells through the in-vivo generation of …See details»
Interius BioTherapeutics Raises $76M Series A Financing to …
PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene …See details»
Interius BioTherapeutics to Present In Vivo CAR Data in Oncology …
Apr 23, 2024 Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced the presentation of preclinical data across six abstracts at the …See details»
Explore careers at Interius | Interius - Interius Biotherapeutics
Join Interius’ fantastic voyage to make a real difference in patient’s lives through next-generation genetic medicines.See details»
Interius BioTherapeutics Announces Successful Manufacturing …
May 9, 2023 Interius BioTherapeutics Develops Wholly Owned Process for Lentiviral Vector Manufacturing; Leverages WuXi Advanced Therapies' ("WuXi ATU") plasmid and lentiviral …See details»
Interius BioTherrapeutics - VentureRadar
Develops innovative techniques for targeted gene delivery in living organisms, focusing on precise cell-specific therapeutic applications. " Interius BioTherapeutics is an early-stage …See details»
Interius BioTherapeutics - Work in biotech
Interius Biotherapeutics is developing cell and gene therapies to treat cancer. Chimeric antigen receptor (CAR) T-cell therapies involve removing and engineering patient T cells to recognise …See details»
Interius BioTherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Privacy Notice - Interius
Nov 26, 2024 We will process your data related to your subscription and payment for the time necessary for the organization of your participation to one of our events. ...See details»
Interius BioTherapeutics Announces Regulatory Approval to …
3 days ago German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to …See details»
Interius BioTherapeutics Announces Regulatory Approval to …
3 days ago For more information, visit www.interiusbio.com and follow us on LinkedIn. Media Contact Michael Rubenstein LifeSci Communications mrubenstein@lifescicomms.com +1 646 …See details»
Learn about our current clinical trials | Interius
INVISE: Injectable Vectors for In Situ Engineering. Talk to your physician if you are interested in a clinical trial. Our phase 1 clinical trial for INT2104 is open and enrolling participants.See details»